**Claims**

What is claimed is:

1. Use of a taxane in the manufacture of a medicament for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, wherein the human patient has received or is receiving treatment comprising a medicament comprising an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19; or use of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, in the manufacture of a medicament for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, wherein the human patient has received or is receiving treatment comprising a medicament comprising a taxane.~~A method of treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer comprising periodically administering to the human patient chemotherapy comprising an amount of a taxane, and 640mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides,~~

~~and has 5-methylcytosines at nucleotides 1, 4, and 19, thereby treating the human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.~~

2. ~~The~~ The use ~~method~~ of claim 1, wherein the taxane is paclitaxel.

3. ~~The~~ The use ~~method~~ of claim 2, wherein ~~during the chemotherapy~~ the ~~amount of~~ medicament comprising paclitaxel

(i) is for intravenous administration to the human patient over a period of 3 hours to provide ~~administered is~~ an amount of paclitaxel which is 200mg/m$^2$ ~~intravenously to the human patient over a period of 3 hours.~~,

~~4. The method of claim 2, wherein during the chemotherapy the amount of paclitaxel~~

(ii) is for intravenous administration to the human patient over a period of 3 hours to provide an amount of paclitaxel which is ~~administered is~~ less than 200mg/m$^2$ ~~intravenously to the human patient.~~,

(iii)

~~5. The method of any one of claims 2-4, wherein during the chemotherapy the paclitaxel~~ is for administration ~~administered~~ to the human patient on the first day of each of up to six three-week chemotherapy cycles, or

(iv) as a combination of (i) and (iii) or (ii) and (iii) above.

~~6. The method of claim 1, wherein the taxane is other than paclitaxel.~~

~~7. The method of claim 6, wherein the taxane is docetaxel, baccatin III, baccatin V, taxol B (cephalomannine), taxol C, taxol D, taxol E, taxol F, taxol G, cabazitaxel, larotaxel, ortataxel (14 beta-hydroxydeacetyl baccatin III), tesetaxel, 10-deacetyl baccatin III, 7-xylosyl-10-deacetyl cephalomannine, 7-xylosyl-10-deacetyl paclitaxel, 10-deacetyl cephalomannine, 7-xylosyl-10-deacetyl taxol C, 10-deacetyl paclitaxel, 7-xylosyl paclitaxel, 10-deacetyl taxol C, 10-deacetyl-7-epi cephalomaunine, 7-xylosyl taxol C, 10-deacetyl-7-epipaclitaxel, 7-epi cephalomaunine, 7-epi paclitaxel, 7-O-methylthiomethyl paclitaxel, 7-deoxy docetaxel, taxanime M, PG-paclitaxel, or DHA-paclitaxel.~~

~~8. The method of claim 7, wherein the taxane is docetaxel.~~

~~9. The method of claim 8, wherein during the chemotherapy the amount of docetaxel administered is 75mg/m2 intravenously to the human patient over a period of 1 hour.~~

~~10. The method of claim 8, wherein during the chemotherapy the amount of docetaxel administered is less than 75mg/m2 intravenously to the human patient.~~

~~11. The method of any one of claims 8-10, wherein during the chemotherapy the docetaxel is administered to the human patient on the first day of each three-week chemotherapy cycle.~~

~~12. The method of claim 7, wherein the taxane is cabazitaxel.~~

~~13~~4. ~~The~~ The use ~~method~~ of any one of claims 1 to ~~12~~3, ~~wherein the chemotherapy further comprises an amount of~~ wherein the human patient has received or is receiving therapy comprising a platinum-based chemotherapeutic agent.

~~14~~5. ~~The~~ The use ~~method~~ of claim ~~13~~4, wherein the platinum-based chemotherapeutic agent is cisplatin, carboplatin (paraplatin),

nedaplatin, oxaliplatin, triplatin tetranitrate, satraplatin, iproplatin, lobaplatin, or picoplatin.

~~15~~6. ~~The~~ The use ~~method~~ of claim ~~14~~5, wherein the platinum-based chemotherapeutic agent is carboplatin and wherein the human patient has received or is receiving therapy comprising carboplatin administered

(i) ~~.~~

~~16. The method of claim 15, wherein during the chemotherapy the amount of carboplatin administered is~~ in an amount of AUC 6mg/mL/min intravenously to the human patient over a period of 30 minutes~~.~~,

(ii)

~~17. The method of claim 15, wherein during the chemotherapy the amount of carboplatin administered is~~ in an amount of less than AUC 6mg/mL/min intravenously to the human patient over a period of 30 minutes~~.~~,

(iii)

~~18. The method of any one of claims 15-17, wherein during the chemotherapy the carboplatin is administered to the human patient~~ on the first day of each of up to six three-week chemotherapy cycles,

(iv) or as a combination of (i) and (iii) or (ii) and (iii) above.

~~19. The method of claim 14, wherein the platinum-based chemotherapeutic agent is cisplatin.~~

~~20. The method of claim 13, wherein the platinum-based chemotherapeutic agent is other than carboplatin.~~

~~21~~7. ~~The~~ The use ~~method~~ of any one of claims ~~13~~ 4 to ~~20~~6, wherein the human patient has received or is receiving therapy comprising ~~during the chemotherapy the~~ a platinum-based chemotherapeutic agent ~~is~~ administered ~~to the human patient~~ on the first day of ~~each~~ a three-week chemotherapy cycle and/or the medicament comprising the ~~.~~

~~22. The method of any one of claims 1 to 21, wherein during the chemotherapy the~~ taxane is for administration~~administered~~ to the human patient on the first day of ~~each~~ a three-week chemotherapy cycle.

~~23. The method of any one of claims 1 to 22, wherein the non-small cell lung cancer is stage IV lung cancer.~~

~~24. The method of any one of claims 1 to 23, wherein the non-small cell lung cancer is of non-squamous histology.~~

~~25. The method of any one of claims 1 to 24, wherein the treating includes prolonging survival of the human patient.~~

~~26. The method of any one of claims 1 to 25, wherein the treating includes prolonging survival of the human patient which prolonged survival is free of progression of the non-small lung cancer.~~

~~27. The method of claim 26, wherein the human patient survives free of progression of the non-small cell lung cancer for at least 14 weeks.~~

~~28. The method of any one of claims 1 to 27, wherein the human patient suffers from chest pain, pleural effusions, pulmonary edema, dyspnea, or hemoptysis.~~

~~29. The method of any one of claims 1 to 28, wherein the non-small cell lung cancer is lung adenocarcinoma or lung large cell carcinoma.~~

~~308~~. ~~The~~ The use ~~method~~ of any one of claims 1 to ~~297~~, wherein the medicament comprising the anti-clusterin oligonucleotide is for administration ~~administered~~ to the human patient intravenously

(i) in an aqueous solution comprising sodium ions~~.~~,

(ii)

~~31. The method of any one of claims 1 to 30, wherein the anti-clusterin oligonucleotide is administered to the human patient~~ 3 times within a 5 to 9 day period before the first day of chemotherapy and then once weekly beginning on the first day of chemotherapy~~.~~,

(iii) in an amount which provides 640 mg of the anti-clusterin oligonucleotide, or

(iv) an combination of (i)-(iii) above.

~~32. The method of any one of claims 1-31, wherein the lung cancer is nonresectable, advanced or metastatic non-small cell lung cancer.~~

~~33. The method of any one of claims 1 to 32, wherein the human patient has not received treatment for non-small cell lung cancer for at least 1 year.~~

~~34. The method of any one of claims 1 to 32, wherein the human patient has not received a chemotherapeutic agent for the treatment of non-small cell lung cancer for at least 1 year.~~

~~35. The method of any one of claims 1 to 32, wherein the human patient has before initiation of the periodic administration received a chemotherapeutic agent for the treatment of lung cancer.~~

~~36. The method of claim 35, wherein the chemotherapeutic agent was a platinum-based chemotherapeutic agent.~~

~~37. The method of any one of claims 1 to 36, further comprising the steps of:~~

~~i) measuring the level of serum clusterin present in the blood of the human patient prior to the administration of the anti-clusterin oligonucleotide;~~

~~ii) determining whether the level of serum clusterin present in the human patient is lower than a predetermined upper threshold level of baseline serum clusterin below which a human patient is likely to substantially benefit from anti-clusterin therapy; and~~

~~iii) administering the anti-clusterin oligonucleotide only if the level of serum clusterin present in the blood of the human patient is lower than the predetermined upper threshold level of baseline serum clusterin.~~

~~38. The method of claim 37, wherein in step i) the measuring is performed after initiation of the chemotherapy.~~

~~39. The method of claim 37, wherein the predetermined upper threshold level of baseline serum clusterin is 75µg/mL.~~

~~40. The method of any one of claims 1 to 39, further comprising the steps of:~~

~~i) administering to the human patient the anti-clusterin oligonucleotide in an initial dosage and treatment protocol;~~

~~ii) thereafter testing the human patient to determine a level of serum clusterin after a period of treatment with the anti-clusterin oligonucleotide intended to reduce clusterin expression;~~

~~iii) determining an adjusted dosage and treatment protocol based on the determined level of serum clusterin; and~~

~~iv) administering to the human patient the anti-clusterin oligonucleotide in accordance with the adjusted dosage and treatment protocol.~~

~~41. The method of claim 40, wherein the determined level of serum clusterin after a period of treatment with the anti-clusterin oligonucleotide intended to reduce clusterin expression is above a predetermined post anti-clusterin oligonucleotide initiation threshold level.~~

~~42. The method claim 40 or 41, wherein the predetermined post anti-clusterin oligonucleotide initiation threshold level is 30µg/mL.~~

~~43. The method of any one of claims 40 to 42, wherein the adjusted dosage and treatment protocol comprises administration of the anti-clusterin oligonucleotide to the human patient two or three times per week.~~

~~44. A combination for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, comprising chemotherapy comprising a taxane and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.~~

~~45~~9. A composition for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, comprising

a) chemotherapy consisting of a taxane and, optionally, a platinum-based chemotherapeutic agent; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-

clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, or.

b)

~~46. A pharmaceutical composition for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, the composition comprising~~ chemotherapy comprising a taxane and, optionally, a platinum-based chemotherapeutic agent, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

~~47. Use of a composition comprising chemotherapy comprising a taxane and, optionally, a platinum-based chemotherapeutic agent, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for treatment of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.~~

~~48. Use of a composition comprising chemotherapy comprising a taxane and, optionally, a platinum-based chemotherapeutic agent, and an~~

~~anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for preparation of a medicament for treatment of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.~~

~~49~~10. A package for use in the treatment of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, comprising chemotherapy comprising a taxane and, optionally, a platinum-based chemotherapeutic agent, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, and instructions for the use of the chemotherapy in combination with the anti-clusterin oligonucleotide for the treatment of unresectable, advanced or metastatic non-small cell lung cancer.

~~50~~11. A chemotherapy comprising a taxane and, optionally, a platinum-based chemotherapeutic agent, for use in combination with an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for treating of a human patient

afflicted with unresectable, advanced or metastatic non-small cell lung cancer; or an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for use in combination with a chemotherapy comprising a taxane and, optionally, a platinum-based chemotherapeutic agent, for treating of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.

~~51. A method of treating a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer comprising periodically administering to the human patient chemotherapy consisting of an amount of paclitaxel and an amount of carboplatin; and 640mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, thereby treating the human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer.~~

~~52. The method of claim 51, wherein the treating includes prolonging survival of the human patient.~~

~~53. The method of claim 51 or 52, wherein the treating includes prolonging survival of the human patient which prolonged survival is free of progression of the non-small lung cancer.~~

~~54. The method of any one of claims 51 to 53, wherein the human patient survives free of progression of the non-small cell lung cancer for at least 14 weeks.~~

~~55. The method of any one of claims 51 to 54, wherein the human patient suffers from chest pain, pleural effusions, pulmonary edema, dyspnea, or hemoptysis.~~

~~56. The method of any one of claims 51 to 55, wherein the non-small cell lung cancer is lung adenocarcinoma or lung large cell carcinoma.~~

~~57. The method of any one of claims 51 to 56, wherein during the chemotherapy the amount of paclitaxel administered is 200mg/m2 intravenously to the human patient over a period of 3 hours.~~

~~58. The method of any one of claims 51 to 57, wherein during the chemotherapy the amount of paclitaxel administered is less than 200mg/m2 intravenously to the human patient.~~

~~59. The method of claim 57 or 58, wherein during the chemotherapy the paclitaxel is administered to the human patient on the first day of each of up to six three-week chemotherapy cycles.~~

~~60. The method of any one of claims 51 to 60, wherein during the chemotherapy the amount of carboplatin administered is AUC 6mg/mL/min intravenously to the human patient over a period of 30 minutes.~~

~~61. The method of any one of claims 51 to 60, wherein during the chemotherapy the amount of carboplatin administered is less than AUC 6mg/mL/min intravenously to the human patient over a period of 30 minutes.~~

~~62. The method of any one of claims 51 to 61, wherein during the chemotherapy the carboplatin is administered to the human patient~~

~~on the first day of each of up to six three-week chemotherapy cycles.~~

~~63. The method of any one of claims 51 to 62, wherein the anti-clusterin oligonucleotide is administered to the human patient intravenously in an aqueous solution comprising sodium ions.~~

~~64. The method of any one of claims 51 to 63, wherein the anti-clusterin oligonucleotide is administered to the human patient 3 times within a 5 to 9 day period before the first day of chemotherapy and then once weekly beginning on the first day of chemotherapy.~~

~~65. The method of any one of claims 51 to 64, wherein the human patient has not received treatment for non-small cell lung cancer for at least 1 year.~~

~~66. The method of any one of claims 51 to 65, wherein the human patient has not received a chemotherapeutic agent for the treatment of non-small cell lung cancer for at least 1 year.~~

~~67. The method of any one of claims 51 to 66, wherein the human patient is afflicted with non-small cell lung cancer of non-squamous histology.~~

~~68. The method of any one of claims 51 to 67, wherein the human patient is afflicted with Stage IV non-small cell lung cancer of non-squamous histology.~~

~~69. The method of any one of claims 51 to 68, further comprising the steps of:~~

~~i) measuring the level of serum clusterin present in the blood of the human patient prior to the administration of the anti-clusterin oligonucleotide;~~

ii) determining whether the level of serum clusterin present in the human patient is lower than a predetermined upper threshold level of baseline serum clusterin below which a human patient is likely to substantially benefit from anti-clusterin therapy; and

iii) administering the anti-clusterin oligonucleotide only if the level of serum clusterin present in the blood of the human patient is lower than the predetermined upper threshold level of baseline serum clusterin.

70. The method of claim 69, wherein in step i) the measuring is performed after initiation of the chemotherapy.

71. The method of claim 69, wherein the predetermined upper threshold level of baseline serum clusterin is 75µg/mL.

72. The method of any one of claims 51 to 71, further comprising the steps of:

i) administering to the human patient the anti-clusterin oligonucleotide in an initial dosage and treatment protocol;

ii) thereafter testing the human patient to determine a level of serum clusterin after a period of treatment with the anti-clusterin oligonucleotide intended to reduce clusterin expression;

iii) determining an adjusted dosage and treatment protocol based on the determined level of serum clusterin; and

iv) administering to the human patient the anti-clusterin oligonucleotide in accordance with the adjusted dosage and treatment protocol.

~~73. The method of claim 72, wherein the determined level of serum clusterin after a period of treatment with the anti-clusterin oligonucleotide intended to reduce clusterin expression is above a predetermined post anti-clusterin oligonucleotide initiation threshold level.~~

~~74. The method of claim 72 or 73, wherein the predetermined post anti-clusterin oligonucleotide initiation threshold level is 30µg/mL.~~

~~75. The method of any one of claims 72 to 74, wherein the adjusted dosage and treatment protocol comprises administration of the anti-clusterin oligonucleotide to the human patient two or three times per week.~~

~~76~~12. A combination for treating a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer, comprising chemotherapy consisting of paclitaxel and carboplatin, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

~~77~~13. A composition for treating a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer, comprising ~~—~~chemotherapy consisting of paclitaxel and carboplatin, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-

17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.~~.~~

~~78. A pharmaceutical composition for treating a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer, the composition comprising chemotherapy consisting of paclitaxel and carboplatin, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.~~

~~79. Use of a composition comprising chemotherapy consisting of paclitaxel and carboplatin, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for treatment of a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer.~~

~~80. Use of a composition comprising chemotherapy consisting of paclitaxel and carboplatin, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for preparation of a medicament for treatment of a human patient afflicted with non-small cell lung~~

~~cancer of non-squamous histology or Stage IV non-small cell lung cancer.~~

~~81~~14. A package for use in the treatment of a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer, comprising chemotherapy consisting of paclitaxel and carboplatin, and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, and instructions for the use of the chemotherapy in combination with the anti-clusterin oligonucleotide for the treatment of non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer.

~~82~~15. A chemotherapy consisting of paclitaxel and carboplatin, for use in combination with an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for treating of a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer; or an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at

nucleotides 1, 4, and 19, for use in combination with a chemotherapy consisting of paclitaxel and carboplatin, for treating of a human patient afflicted with non-small cell lung cancer of non-squamous histology or Stage IV non-small cell lung cancer.

~~83. A method of treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer comprising periodically administering to the human patient chemotherapy comprising an amount of docetaxel; and 640mg of an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, thereby treating the human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.~~

~~84. The method of claim 83, wherein the treating includes prolonging survival of the human patient.~~

~~85. The method of claim 83 or 84, wherein the treating includes prolonging survival of the human patient which prolonged survival is free of progression of the non-small cell lung cancer.~~

~~86. The method of claim 85, wherein the human patient survives free of progression of the non-small cell lung cancer for at least 14 weeks.~~

~~87. The method of any one of claims 83 to 86, wherein the human patient suffers from chest pain, pleural effusions, pulmonary edema, dyspnea, or hemoptysis.~~

~~88. The method of any one of claims 83 to 87, wherein the non-small cell lung cancer is lung adenocarcinoma or lung large cell carcinoma.~~

~~89. The method of any one of claims 83 to 88, wherein during the chemotherapy the amount of docetaxel administered is 75mg/m2 intravenously to the human patient over a period of 1 hour.~~

~~90. The method of any one of claims 83 to 88, wherein during the chemotherapy the amount of docetaxel administered is less than 75mg/m2 intravenously to the human patient.~~

~~91. The method of any one of claims 83 to 90, wherein during the chemotherapy the docetaxel is administered to the human patient on the first day of each of at least one three-week chemotherapy cycle.~~

~~92. The method of any one of claims 83 to 91, wherein the anti-clusterin oligonucleotide is administered to the human patient intravenously in an aqueous solution comprising sodium ions.~~

~~93. The method of claim 92, wherein the anti-clusterin oligonucleotide is administered to the human patient 3 times within a 5 to 9 day period before the first day of chemotherapy and then once weekly beginning on the first day of chemotherapy.~~

~~94. The method of any one of claims 83 to 93, wherein the lung cancer is nonresectable, advanced or metastatic non-small cell lung cancer.~~

~~95. The method of any one of claims 83 to 94, wherein the human patient has not received treatment for non-small cell lung cancer for at least 1 year.~~

~~96. The method of any one of claims 83 to 95, wherein the human patient has not received a chemotherapeutic agent for the treatment of non-small cell lung cancer for at least 1 year.~~

~~97. The method of any one of claims 83 to 96, wherein the human patient has before initiation of the periodic administration received a chemotherapeutic agent for the treatment of lung cancer.~~

~~98. The method of claim 97, wherein the chemotherapeutic agent was a platinum-based chemotherapeutic agent.~~

~~99. The method of any one of claims 83 to 98, wherein the human patient is afflicted with Stage IV non-small cell lung cancer.~~

~~100. The method of any one of claims 83 to 99, wherein the human patient is afflicted with non-small cell lung cancer of non-squamous histology.~~

~~101. The method of any one of claims 83 to 100, further comprising the steps of:~~

~~i) measuring the level of serum clusterin present in the blood of the human patient prior to the administration of the anti-clusterin oligonucleotide;~~

~~ii) determining whether the level of serum clusterin present in the human patient is lower than a predetermined upper threshold level of baseline serum clusterin below which a human patient is likely to substantially benefit from anti-clusterin therapy; and~~

~~iii) administering the anti-clusterin oligonucleotide only if the level of serum clusterin present in the blood of the human patient is lower than the predetermined upper threshold level of baseline serum clusterin.~~

~~102. The method of claim 101, wherein in step i) the measuring is performed after initiation of the chemotherapy.~~

~~103. The method of claim 101, wherein the predetermined upper threshold level of baseline serum clusterin is 75µg/mL.~~

~~104. The method of any one of claims 83 to 103, further comprising the steps of:~~

~~i) administering to the human patient the anti-clusterin oligonucleotide in an initial dosage and treatment protocol;~~

~~ii) thereafter testing the human patient to determine a level of serum clusterin after a period of treatment with the anti-clusterin oligonucleotide intended to reduce clusterin expression;~~

~~iii) determining an adjusted dosage and treatment protocol based on the determined level of serum clusterin; and~~

~~iv) administering to the human patient the anti-clusterin oligonucleotide in accordance with the adjusted dosage and treatment protocol.~~

~~105. The method of claim 104, wherein the determined level of serum clusterin after a period of treatment with the anti-clusterin oligonucleotide intended to reduce clusterin expression is above a predetermined post anti-clusterin oligonucleotide initiation threshold level.~~

~~106. The method of claim 104 or 105, wherein the predetermined post anti-clusterin oligonucleotide initiation threshold level is 30µg/mL.~~

~~107. The method of any one of claims 104 to 106, wherein the adjusted dosage and treatment protocol comprises administration of the~~

anti-clusterin oligonucleotide to the human patient two or three times per week.

108. A combination for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, comprising chemotherapy comprising docetaxel; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGACTGTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

109. A composition for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, comprising chemotherapy comprising docetaxel; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGACTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

110. A pharmaceutical composition for treating a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, the composition comprising chemotherapy comprising docetaxel; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGACTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19.

111. Use of a composition comprising chemotherapy comprising docetaxel; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for treatment of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.

112. Use of a composition comprising chemotherapy comprising docetaxel; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for preparation of a medicament for treatment of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.

113. A package for use in the treatment of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer, comprising chemotherapy comprising docetaxel; and an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, and instructions for the use of the chemotherapy in combination with the anti-clusterin

oligonucleotide for the treatment of unresectable, advanced or metastatic non-small cell lung cancer.

114. A chemotherapy comprising docetaxel for use in combination with an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for treating of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer; or an anti-clusterin oligonucleotide having the sequence CAGCAGCAGAGTCTTCATCAT (Seq. ID No.: 1), wherein the anti-clusterin oligonucleotide has a phosphorothioate backbone throughout, has sugar moieties of nucleotides 1-4 and 18-21 bearing 2'-O-methoxyethyl modifications, has nucleotides 5-17 which are 2'deoxynucleotides, and has 5-methylcytosines at nucleotides 1, 4, and 19, for use in combination with a chemotherapy comprising docetaxel, for treating of a human patient afflicted with unresectable, advanced or metastatic non-small cell lung cancer.